NGF and BDNF: from nerves to adipose tissue, from neurokines to metabokines

Rivista di Psichiatria

Volumn 44, Issue 2, 2009, Pages 79-87

  Chaldakov, George N ^a   Tonchev, Anton B ^a   Aloe, Luigi ^b  

^a MEDICAL UNIVERSITY OF VARNA   (Bulgaria)

^b EUROPEAN BRAIN RESEARCH INSTITUTE   (Italy)

Author keywords

Adipokines; Ampakines; Calorie restriction; Deacetylase; Metabotrophic effects; Neurotrophins; Synaptotrophic effects

Indexed keywords

ADIPOCYTOKINE; ANGIOPOIETIN 1; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METALLOTHIONEIN; NERVE GROWTH FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; VASCULOTROPIN;

ADIPOSE TISSUE; ANOREXIA NERVOSA; ATHEROSCLEROSIS; AUTISM; BULIMIA; CALORIC RESTRICTION; DEMENTIA; DEPRESSION; HEART DISEASE; HUMAN; MENTAL DISEASE; METABOLIC DISORDER; NERVOUS TISSUE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; RETT SYNDROME; REVIEW; SCHIZOPHRENIA;

ADIPOSE TISSUE; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; HUMANS; NERVE GROWTH FACTOR; NERVOUS SYSTEM PHYSIOLOGICAL PHENOMENA;

EID: 67449113290     PISSN: 00356484     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (164)

1. Levi-Montalcini R: The nerve growth factors 35 years later. Science, 1987,237,1154-1162.
2. Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A: Nerve growth factor: from neurotrophin to neurokine. Trends of Neuroscience, 1996,19,514-520.
3. Levi-Montalcini R: The saga of the nerve growth factor. Neuroreport, 1998,9, R71-83.
4. Levi-Montalcini R: From Turin to Stockholm via St. Louis and Rio de Janeiro. Science, 2000,287,809.
5. Aloe L, Chaldakov GN (eds): Nerve growth factor in health and disease. Biomedical Reviews, 1999,10.
6. Aloe L, Calza L (eds): NGF and related molecules in health and disease. Progress in Brain Research, 2004,146.
7. Scarisbrick IA, Jones EG, Isackson PJ: Coexpression of mRNAs for NGF, BDNF, and NT-3 in the cardiovascular system of the pre- and postnatal rat. Journal of Neuroscience, 1993,13,875-893.
8. Abe T, Morgan DA, Gutterman DD: Protective role of nerve growth factor against postischemic dysfunction of sympathetic coronary innervation. Circulation, 1997,95,13-20.
9. Matsuda H, Koyama H, Sato H, Sawada J, Itakura A, Tanaka A, et al.: Role of nerve growth factor in cutaneous wound healing: accelerating effects in normal and healing-impaired diabetic mice. Journal of Experimental Medicine, 1998,187,297-306.
10. Chaldakov GN, Stankulov IS, Hristova M, Ghenev PI: Adipobiology of disease: adipokines and adipokine-targeted pharmacology. Current Pharmaceutical Design, 2003,9,1023-1031.
11. Chaldakov GN, Fiore M, Tonchev AB, Dimitrov D, Pancheva R, Ran i G, et al.: Homo obesus: a metabotrophin-deficient species. Pharmacology and nutrition insight. Current Pharmaceutical Design, 2007,13,2176-2179.
12. Chaldakov GN, Fiore M, Ghenev PI, Sornelli F, Tonchev AB, Aloe L: Neural-immune-endocrine (NIE) interactions in vascular biology: neurotrophins, immune cells, and tunica adiposa. Journal of Endo Cardiology press.
13. Generini S, Tuveri MA, Cerinic M, Mastinu F, Manni L, Aloe L: Topical application of nerve growth factor in human diabetic foot ulcers. A study of three cases. Experimental and Clinical Endocrinology and Diabetes, 2004,112,542-544.
14. Muangman P, Muffley LA, Anthony JP, Spenny ML, Underwood RA, Olerud JE, et al.: Nerve growth factor accelerates wound healing in diabetic mice. Wound Repair Regeneration, 2004,12,44-52.
15. Larrieta ME, Vital P, Mendoza-Rodriguez A, Cerbon M, Hiriart M: Nerve growth factor increases in pancreatic beta cells after streptozotocin-induced damage in rats. Experimental Biology and Medicine, 2006,231,396-402.
16. Kangavari S, Oh YS, Zhou S, Youn HJ, Lee MY, Jung WS, et al.: Radiofrequency catheter ablation and nerve growth factor concentration in humans. Heart Rhythm, 2006,3,1150-1155.
17. Corsi MM, Dogliotti G, Pedroni F, Palazzi E, Magni P, Chiappelli M, et al.: Plasma nerve growth factor (NGF) and inflammatory cytokines (IL-6 and MCP-1) in young and adult subjects with Down syndrome: an interesting pathway. NeuroEndocrinology Letters, 2006,27,773-778.
18. Manni L, Di Fausto V, Chaldakov GN, Aloe L: Brain leptin and nerve growth factor. Are differently affected by stress in male and female mice: possible neuroendocrine and cardio-metabolic implications. Neuroscience Letters, 2007,426,39-44.
19. Töre F, Tonchev AB, Fiore M, Tunçel N, Atanassova P, Aloe L, et al.: From adipose tissue protein secretion to adipopharmacology of disease. Immunology Endocrine & Metabolic Agents in Medical Chemistry, 2007,7,149-155.
20. Sposato V, Manni L, Chaldakov GN, Aloe L: Streptozotocin-induced diabetes is associated with changes in NGF levels in pancreas and brain. Archives Italiennes de Biologie, 2007,145, 87-97.
21. Gómez-Pinilla F: Brain foods: the effects of nutrients on brain function. Nature Reviews Neuroscience, 2008,9,568-578.
22. Caporali A, Sala-Newby GB, Meloni M, Graiam" G, Pani E, Cristofaro B, et al.: Identification of the prosurvival activity of nerve growth factor on cardiac myocytes. Cell Death and Differentiation, 2008,15,299-311.
23. Sornelli F, Fiore M, Chaldakov GN, Aloe L: Brain-dervied neurotrophic factor: a new adipokine. Biomedical Reviews, 2007, 18,85-88.
24. Angeletti PU, Levi-Montalcini R, Calissano P: The nerve growth factor (NGF): chemical properties and metabolic effects. Advances in Embryology and Related Areas of Molecular Biology, 1968,31,51-75.
25. Mukherjee SP, Mukherjee C: Similar activities of nerve growth factor and its homologue proinsulin in intracellular hydrogen peroxide production and metabolism in adipocytes. Transmembrane signalling relative to insulin-mimicking effects. Biochemical Pharmacology, 1982,31,3163-3172.
26. Lukashev D, Ohta A, Apasov S, Chen JF, Sitkovsky M: Cutting edge: Physiologic attenuation of proinflammatory transcription by the Gs protein-coupled A2A adenosine receptor in vivo. Journal of Immunology, 2004,173,21-24.
27. Chao MV, Rajagopal R, Lee FS: Neurotrophin signalling in health and disease. Clinical Science (London), 2006,110,167-173.
28. Jeanneteau P, Chao MV: Promoting neurotrophic effects by GPCR ligands. Novartis Foundation Symposium, 2006, 276,181-189.
29. Mojsilovic-Petrovic J, Arneja A, Kalb RG: Enprofylline protects motor neurons from in vitro excitotoxic challenge. Neurodegenerative Diseases, 2005,2,160-165.
30. Aloe L, Levi-Montalcini R: Mast cells increase in tissues of neonatal rats injected with the nerve growth factor. Brain Research, 1977,133,358-366.
31. Chaldakov GN: The NGF is wider than the neuron. Archives Italian of Biology, 2003,141,89-92.
32. Aloe L, Tirassa P, Bracci-Laudiero L: Nerve growth factor in neurological and non neurological diseases: basic findings and emerging pharmacological prospectives. Current Pharmaceutical Design, 2001,7,113-123.
33. Bono F, Lamarche I, Herbert JM: NGF exhibits a proapoptotic activity for human vascular smooth muscle that is inhibited by TGF-βi. FEBS Letters, 1997,416,243-246.
34. Lazarovici P, Marcinkiewicz C, Lelkes PI: Cross talk between the cardiovascular and nervous systems: neurotrophic effects of vascular endothelial growth factor (VEGF) and angiogenic effects of nerve growth factor (NGF) - implications in drug development. Current Pharmaceutical Design, 2006,12,2609-2622.
35. Hansen-Algenstaedt N, Algenstaedt P, Schaefer C, Hamann A, Wolfram L, Cingöz G, et al.: Neural driven angiogenesis by overexpression of nerve growth factor. Histochemistry and Cell Biology, 2006,125,637-649.
36. Botchkarev VA, Botchkareva NV, Peters EMJ, Paus R: Epithelial growth control by neurotrophins: leads and lessons form the hair follicle. Progress in Brain Research, 2004,146,493-513.
37. Wang B, Jenkins JR, Trayhurn P: Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: integrated response to TNF-. American Journal of Physiology Endocrinology and Metabolism, 2005, 288,E731-E740.
38. Bull6 M, Peeraully MR, Trayhurn P: Stimulation of NGF expression and secretion in 3T3-L1 adipocytes by prostaglandins PGD2, PGJ2, and Deltal2-PGJ2. American Journal of Physiology, Endocrinology and Metabolism, 2005,289, E62-67.
39. Bull6 M, Peeraully MR, Trayhurn P, Folch J, Salas-Salvad6 J: Circulating nerve growth factor levels in relation to obesity and the metabolic syndrome in women. European Journal of Endocrinology, 2007,157,303-310.
40. Fahnestock M, Yu G, Coughlin MD: ProNGF: a neurotrophic or an apoptotic molecules? Progess in Brain Research, 2004, 146,101-110.
41. Tsai SJ: Statins may enhance the proteolytic cleavage of proBDNF: implications for the treatment of depression. Medical Hypotheses, 2007,68,1296-1299.
42. Aloe L, Alleva E, Bohm A, Levi-Montalcini R: Aggressive behaviour induces release of nerve growth factor from mouse salivary gland into blood stream. Proceedings of National Academy of Sciences USA, 1986,83,6184-6187.
43. Aloe L: Nerve growth factor, human skin ulcers and vascularization. Our experience. Progress in Brain Research, 2004,146, 515-522.
44. Raab S, Plate KH: Different networks, common growth factors: shared growth factors and receptors of the vascular and the nervous system. Acta Neuropathologica, 2007,113,607-626.
45. Lu B: Acute and long-term synaptic modulation by neurotrophins. Progess in Brain Research, 2004,146,137-150.
46. Soule' J, Messaoudi E, Bramham CR: Brain-derived neurotrophic factor and control of synaptic consolidation in the adult brain. Biochemical Society Transections, 2006,34 (Pt 4), 600-604.
47. Lynch G, Rex CS, Chen LY, Gall CM: The substrate of memory: Defects, treatments, and enhancement. European Journal of Pharmacolology, 2008,585,2-13.
48. Micera A, Vigneti E, Pickholtz D, Reich R, Pappo O, Bonini S, et al.: Nerve growth factor displays stimulatory effects on human skin and lung fibroblasts, demonstrating a direct role for this factor in tissue repair. Proceedings of National Academy of Science of USA, 2001,98,6162-6167.
49. Aloe L, Tirassa P, Lambiase A: The topical application of nerve growth factor as a pharmacological tool for human corneal and skin ulcers. Pharmacological Research, 2008,57,253-258.
50. Lebrun B, Bariohay B, Moyse E, Jean A: Brain-derived neurotrophic factor (BDNF) and food intake regulation: a minireview. Autonomic Neuroscience, 2006,126-127,30-38.
51. Fujinami A, Ohta K, Obayashi H, Fukui M, Hasegawa G, Na- kamura N, et al.: Serum brain-derived neurotrophic factor in patients with type 2 diabetes mellitus: relationship to glucose metabolism and biomarkers of insulin resistance. Clinical Biochemistry, 2008,41,812-817.
52. Watson GS, Craft S: The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs, 2003,17,27-45.
53. Craft S: Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Current of Alzheimer Research, 2007,4,147-152.
54. G6ra-Kupilas K, Jo ko J: The neuroprotective function of vascular endothelial growth factor (VEGF). Folia Neuropatho- logica, 2005,43,31-39.
55. Otten U, Gadient RA: Neurotrophina and cytokines-intermediaties between the immune and nervous systems. International Journal of Developmental Neuroscience, 1995,13,147-151.
56. Shintani F: Cytokines and neurotrophins in psychiatric disorders. Biomedical Reviews, 1999,10,69-73.
57. Tang BL: Leptin as a neuroprotective agent. Biochemical and Biophysic Research Communications, 2008,368,181-185.
58. Lu XY: The leptin hypothesis of depression: a potential link between mood disorders and obesity? Current Opinion in Pharmacology, 2007,7,648-652.
59. Reid PC, Uramo Y, Kodama T, Hamakubo T: Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins. Journal of Cellular and Molecular Medicine, 2007,11,383-392.
60. Xiong H, Callaghan D, Jones A, Walker DG, Lue LF, Beach TG, et al.: Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiology of Disease, 2008,29,422-437.
61. Nelson TJ, Alkon DL: Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration. Biochemical Society Transactions, 2005,33,1033-1036.
62. Perry TA, Greig NH: A new Alzheimer's disease interventive strategy: GLP-1. Current Drug Targets, 2004,5,565-571.
63. Bissels GJ, Staekonborg S, Brunner E, Brayne C, Sheltens P: Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurology, 2006,5, 64-74.
64. Sima AA, Li ZG: Diabetes and Alzheimer's disease - is there a connection? Review of Diabetes Study, 2006,3,161-168.
65. Simon GE, Von Korff M, Saunders K, Miglioretti DL, Crane PK, van Belle G, et al.: Association between obesity and psychiatric disorders in the US adult population. Archives of General Psychiatry, 2006,63,824-830.
66. Li L, Holscher C: Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain Research Reviews, 2007,56,384-402.
67. Li ZG, Zhang W, Sima AA: Alzheimer-like changes in rat model of spontaneous diabetes. Diabetes, 2007,56,1817-1824.
68. Luchsinger JA, Mayeux R: Adiposity and Alzheimer's disease. Current Alzheimer Research, 2007,4,127-134.
69. Whitmer RA: The epidemiology of adiposity and dementia. Current Alzheimer Research, 2007,4,117-122.
70. Beydoun MA, Beydoun HA, Wang Y: Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis. Obesity Review,2008,9,204-218.
71. Petry NM, Barry D, Pietrzak RH, Wagner JA: Overweight and obesity are associated with psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosomatic Medicine, 2008,70,288-297.
72. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM: Intracerebral streptozotocin model of type 3 diabetes: relevance to sporatic Alzheimer's disease. Journal of Alzheimer's Disease, 2006,9,13-33.
73. Kolotkin RL, Corey-Lisle PK, Crosby RD, Swanson JM, Tuo- mari AV, LTtalien GJ, et al.: Impact of obesity on health-related quality of life in schizophrenia and bipolar disorders. Obesity, 2008,16,749-754.
74. Calamandrei G, Alleva E, Cirulli F, Queyras A, Volterra V, Capirci O, et al.: Serum NGF levels in children and adolescents with either Williams syndrome or Down syndrome. Developmental Medicine and Child Neurolology, 2000,42, 746- 750.
75. Huang Y, Doherty JJ, Dingledine R: Altered histone acetylation at glutamate receptor 2 and brain-derived neurotrophic factor genes is an early event triggered by status epilepticus. Journal of Neuroscience, 2002,22,8422-8428.
76. Villoslava P, Genain CP: Role of nerve growth factor and other trophic factors in brain inflammation. Progress in Brain Research, 2004,146,403-414.
77. Monteleone P, Fabrazzo M, Martiadis V, Serritella C, Pannuto M, Maj M: Circulating brain-derived neurotrophic factor is decreased in women with anorexia and bulimia nervosa but not in women with binge-eating disorder: relationships to co- morbid depression, psychopathology and hormonal variables. Psychological Medicine, 2005,35,897-905.
78. Hashimoto K, Koizumi H, Nakazato M, Shimizu E, Iyo M: Role of brain-derived neurotrophic factor in eating disorders: recent findings and its pathophysiological implications. Progress in Neuropsychopharmacology and Biological Psychiatry, 2005, 29,499-504.
79. Blandini F, Rinaldi L, Tassorelli C, Sances G, Motta M, Samue- le A, et al.: Peripheral levels of BDNF and NGF in primary headaches. Cephalalgia, 2006,26,136-142.
80. Chang Q, Khare G, Dani V, Nelson S, Jaenisch R: The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron, 2006,49,341-348.
81. Manning S: Diabetes and dementia: a common link of coincidental coexistence. Biomedical Reviews, 2007,18,59-64.
82. Chen Y, Yang R, Yao L, Sun Z, Wang R, Dai I: Diffrential expression of neurotrophins in penises of streptozotocin-induced diabetic rats. Journal of Andrology, 2007,28,306-312.
83. Sarchielli P, Mancini ML, Floridi A, Coppola F, Rossi C, Nardi K, et al.: Increased levels of neurotrophins are not specific for chronic migraine: evidence from primary fibromyalgia syndrome. Journal of Pain, 2007,8,737-745.
84. Mercader JM, Fernandez-Aranda F, Gratacbs M, Ribases M, Badia A, Villarejo C, et al.: Blood levels of brain-derived neurotrophic factor correlate with several psychopathological symptoms in anorexia nervosa patients. Neuropsychobiology, 2007,56,185-190.
85. Ahmed F, Tessarollo L, Thiele C, Mocchetti I: Brain-derived neurotrophic factor modulates expression of chemokine receptors in the brain. Brain Research, 2008,1227,1-11.
86. Azoulay D, Urshansky N, Karni A: Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection. Journal of Neuroimmunology, 2008,195,186-193.
87. Lu B, Martinowich K: Cell biology of BDNF and its relevance to schizophrenia. Novartis Foundation Symposium, 2008,289, 119-129.
88. Makar TK, Trisler D, Sura KT, Sultana S, Patel N, Bever CT: Brain derived neurotrophic factor treatment reduces inflammation and apoptosis in experimental allergic encephalomyelitis. Journal of Neurological Science, 2008,270,70-76.
89. Ognibene E, Adriani W, Caprioli A, Ghirardi O, Ali SF, Aloe L, et al.: The effect of early maternal separation on brain-derived neurotrophic factor and monoamine levels in adult heterozygous reeler mice. Progress in Neuropsychopharmacology and Biological Psychiatry, 2008,32,1269- 1276.
90. Martinowich K, Lu B: Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology, 2008, 33,73-83.
91. Post JI, Eibl JK, Ross GM: Zinc induces motor neuron death via a selective inhibition of brain-derived neurotrophic factor activity. Amyotrophic Lateral Sclersis, 2008,9,149-155.
92. Karamoysoyli E, Burnand RC, Tomlison DR, Gardiner NJ: Neuritin mediates nerve growth factor-induced axonal regeneration and is deficient in experiemantal diabetic neuropathy. Diabetes, 2008,57,181-189.
93. Park KS, Kim SS, Kim JC, Kim HC, Im YS, Ahn CW, et al.: Serum and tear level of nerve growth factor in diabetic retinopathy patients. American Journal of Ophthalmology, 2008,145, 432-437.
94. Groves JO: Is it time to reassess the BDNF hypothesis of depression? Molecular Psychiatry, 2007,12,1079-1088.
95. Zhou, et al.: 2008.
96. Rex CS, Lin CY, Kramar EA, Chen LY, Gall CM, Lynch. G: Brain-derived neurotrophic factor promotes long-term potentiation-related cytoskeletal changes in adult hippocampus. Journal of Neuroscience, 2007,27,3017-3029.
97. Chapleau CA, Carlo ME, Larimore JL, Pozzo-Miller L: The actions of BDNF on dendritic spine density and morphology in organotypic slice cultures depend on the presence of serum in culture media. Journal of Neuroscience Methods, 2008, 169, 182-190.
98. Tyler WJ, Perrett SP, Pozzo-Miller LD: The role of neurotrophins in neurotransmitter release. Neuroscientist, 2002,8, 524-531.
99. G6mez-Palacio Schjetnan A, Escobar-Rodriguez ML: Memory coding and retention: brain-derived neurotrophic factor (BDNF) in synaptic plasticity. Revista de Neurologia, 2007,45, 409-417.
100. Tongiorgi E: Activity-dependent expression of brain-dervied neurotrophic factor in dendrites: Facts and open questions. Neuroscience Research, 2008,61,335-346.
101. Snider WD, Lichtman JW: Are neurotrophins synaptotro- phins? Molecular and Cellular Neuroscience, 1996,7,433-442.
102. Lynch G: Glutamate-based therapeutic approaches: ampakines. Current Opinion in Pharmacology, 2006,6,82-88.
103. Chaldakov GN, Fiore M, Hristova MG, Aloe L: Metabotrophic potential of neurotrophins: implication in obesity and related diseases? Medical Science Monitor, 2003,9, HY19-21.
104. Williams LR: Hypophagia is induced by intracerebroventricular administration of nerve growth factor. Experimental Neurology, 1991,113,31-37.
105. Ham, et al.: 2006.
106. Nicholson JR, Peter JC, Lecourt AC, Barde YA, Hofbauer KG: Melanocortin-4 receptor activation stimulates hypothalamic brain-derived neurotrophic factor release to regulate food intake, body temperature and cardiovascular function. Journal of Neuroendocrinology, 2007,19,974-982.
107. Yamanaka M, Itakura Y, Tsuchida A, Nakagawa T, Noguchi H, Taiji M: Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice. Diabetes Obesity and Metabolism, 2007,9,879-888.
108. Yamanaka M, Itakura Y, Ono-Kishino M,Tsuchida A, Nakagawa T, Taiji M: Intermittent administration of brain-derived neurotrophic factor (BDNF) ameliorates glucose metabolism and prevents pancreatic exhaustion in diabetic mice. Journal of Bioscience and Bioengenering, 2008,105,395-402.
109. Xu, et al.: 2003.
110. Bariohay B, Lebrun B, Moyse E, Jean A: Brain-derived neurotrophic factor plays a role as an anorexigenic factor in the dorsal vagal complex. Endocrinology, 2005,146,5612-5620.
111. Falcini F, Cerinic MM, Ermini M, Generini S, Lombardi A, Pig- none A, et al.: Nerve growth factor circulating levels are increased in Kawasaki disease: correlation with disease actvity and reduced angiotensin converting enzyme levels. Journal of Rheumatology, 1996,23,1798-1802.
112. Chaldakov GN, Fiore M, Stankulov IS, Manni L, Hristova MG, Antonelli A, et al.: Neurotrophin presence in human coronary atherosclerosis and metabolic syndrome: a role for NGF and BDNF in cardivascualr disease? Progress in Brain Research, 2004,146,279-289.
113. Geroldi D, Minoretti P, Emanuele E: Brain-derived neurotrophic factor and the metabolic syndrome: more than just hypothesis. Medical Hypotheses, 2006,67,195-196.
114. Hasan W, Jama A, Donohue T, Wernli G, Onyszchuk G, Al-Ha-fez B, et al.: Sympathetic hyperinnervation and inflammatory cell NGF synthesis following myocardial infarction in rats. Brain Research, 2006,1124,142-154.
115. Manni L, Nikolova V, Vyagova D, Chaldakov GN, Aloe L: Reduced plasma levels of NGF and BDNF in patients with acute coronary syndromes. International Journal of Cardiology, 2005,102,169-171.
116. Krabbe KS, Nielsen AR, Krogh-Madsen R, Plomgaard P, Rasmussen P, Erikstrup C, et al.: Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia, 2007, 50, 431- 438.
117. Pedersen BK: Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia, 2007,50,431-438.
118. Schulte-Herbruggen O, Braun A, Rochlitzer S, Jockers-Scherubl MC, Hellweg R: Neurotrophic factors: a tool for therapeutic strategies in neurological, neuropsychiatric and neuroimmunological diseases? Current Medicinal Chemistry, 2007,14, 2318-2329.
119. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue. Nature, 1994,372,425-432.
120. Trayhurn P, Wood IS: Adipokines: inflammation and pleiotrop- ic role of white adipose tissue. British Journal of Nutrition, 2004,92,347-355.
121. Catalan V, Rodriguez A, Becerril S, Sainz N, Gomez-Ambrosi J, Fruhbeck G: Adipopharmacology of inflammation and insulin resistance. Biomedical Reviews, 2006,17,43-51.
122. Guzik TJ, Marvar PJ, Czesnikiewicz-Guzik M, Korbut R: Perivascular adipose tissue as a messenger of the brain-vascular axis: role in vascular inflammation and dysfunction. Journal of Physiology and Pharmacology, 2007,58,591-610.
123. Iacobellis G, Sharma AM: Epicardial adipose tissue as new cardio-metabolic risk marker and potential therapeutic target in the metabolic syndrome. Current Pharmaceutical Design, 2007,13,2180-2184.
124. Schaffler A, Scholmerich J, Buechler C: Hypothesis paper. Brain talks with fat - evidence for a hypothalamic-pituitary- adipose axis? Neuropeptides, 2005,39,363-367.
125. Schaffler A, Scholmerich J, Buechler C: The role of " adipotrophins" and the clinical importance of a potential hypothalamic-pituitary-adipose axis. Nature Clinical Practic En- docrinolology and Metabolism, 2006,2,374-383.
126. Wilkinson M, Brown R, Imran SA, Ur E: Adipokine gene expression in brain and pituitary gland. Neuroendocrinology, 2007,86,191-209.
127. Brown R, Thompson HJ, Imran SA, Ur E, Wilkinson M: Traumatic brain injury induces adipokine gene expression in rat brain. Neuroscience Letters, 2008,432,73-78.
128. Di Fausto V, Fiore M, Tirassa P, Lambiase A, Aloe L: Eye drop NGF administration promotes the recovery of chemically injured cholinergic neurons of adult mouse forebrain. European Journal of Neuroscience, 2007,26,2473-2480.
129. Geerts H: ATT-082 (NeoTherapeutics Inc). Drugs, 1998,1,694- 699.
130. Angelucci F, Mathe AA, Aloe L: Neurotophic factors and CNS disorders: findings in rodent models of depression and schizophrenia. Progress in Brain Research, 2004,146,151-165.
131. Rantamaki T, Castren E: Targeting TrkB neurotrophin receptor to treat depression. Expert Opinions in Therapeutic Targets, 2008,13,705-715.
132. Kozisek ME, Middlemas D, Bylund DB: Brain-dervied neurotrophic facts and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies. Pharmacology and Therapy, 2008,117,30-51.
133. Sun MK, Alkon DL: Effects of 4-methylcatechol on spatial memory and depression. Neuroreport, 2008,19,355-359.
134. Fiore M, Di Fausto V, Iannitelli A, Aloe L: Clozapine or haloperidol in rats prenatally exposed to methylazoxymethanol, a compound inducing entorhinal-hippocampal deficits, alter brain and blood neurotrophins' concentrations. Annals of Institute Superior Sanita, 2008,44,167-177.
135. Danysz W: CX-516 Cortex pharmaceuticals. Current Opinion in Investigation of Drugs, 2002,3,1081-1088.
136. Lynch G, Gall CM: Ampakines and the threefold path to con- gnitive enhacement. Trends in Neuroscience, 2006,29,554-562.
137. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ: Sustained hippocampal chromatin regulation in mouse model of depression and antidepressant action. Nature Neuroscience, 2006,9,519-525.
138. Taniura H, Sng JC, Yoneda Y: Histone modifications in status epilepticus induced by kainate. Histolology and Histopatholo- gy, 2006,21,785-791.
139. Schroeder FA, Lin CL, Crusio WE, Akbarian S: Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biological Psychiatry, 2007, 62, 55-64.
140. Dompierre JP, Godin JD, Charrin BC, Cordelieres FP, King SJ, Humbert S, et al.: Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. Journal of Neuroscience, 2007, 27, 3571-3583.
141. Mattson MP, Duan W, Guo Z: Meal size and frequency affect neuronal plasticity and vulnerability to disease: cellular and molecular mechanisms. Journal of Neurochemistry, 2003,84,417-431.
142. Wang J, Ho L, Qin W, Rocher AB, Seror I, Humala N, et al.: Caloric restriction attenuates beta-amyloid neuropathology in mouse model of Alzheimer's disease. FASEB Journal, 2005,19, 659-661.
143. Koizumi H, Hashimoto K, Iyo M: Dietary restriction changes behaviours in brain-derived neurotrophic factor heterozygous mice: role of serotonergic system. European Journal of Neuroscience, 2006,24,2335-2344.
144. Pasinetti GM, Zhao Z, Qin W, Ho L, Shrishailam Y, Macgrogan D, et al.: Caloric intake and Alzheimer's disease. Experimental approaches and therapeutic implications. Interdisciplinary Topics in Gerontology, 2007,35,159-175.
145. Kanoski SE, Meisel RL, Mullins AJ, Davidson TL: The effects of energy-rich diets on discrimination reversal learning and on BDNF in the hippocampus and prefrontal cortex of the rat. Behavioral Brain Research, 2007,182,57-66.
146. Plunet WT, Streijger F, Lam CK, Lee JH, Liu J, Tetzlaff W: Dietary restriction started after spinal cord injury improves functional recovery. Experimental Neurology, 2008,213,28-35.
147. Tang SW, Chu E, Hui T, Helmeste D, Law C: Influence of exercise on serum brain-dervied neurotrophic factor concentrations in healthy human subjects. Neuroscience Letters, 2008, 431,62-65.
148. Molteni R, Barnard RJ, Ying Z, Roberts CK, Gomez-Pinilla F: A high-fat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity, and learning. Neuroscience, 2002,112,803-814.
149. O'Brian CA, Chu F: Molecular targets of resveratrol: Implications to health and disease prevention. In: Aggarwal BB, Shishodia S (eds). Resveratrol in Health and Disease. CRC Press, Taylor & Francis Group, Boca Raton, FL, 2006, pp. 133-178.
150. Nikolova V: Resveratrol: a crossroad of enology and biomedicine. Biomedical Reviews, 2007,18,89-101.
151. Tonchev AB: Fatty acids as regulators of hippocampal neurogenesis: the case of GPCR40. Biomedical Reviews, 2007,18,69-73.
152. Whitefield JF: Can statins put the brakes on Alzheimer's disease? Expert Opinions in Investigating Drugs, 2006,15,1479- 1485.
153. Bifulco M, Malfitano AM, Marasco G: Potential therapeutic role of statins in neurological disorders. Expert Review in Neurotherapy, 2008,8,827-837.
154. Arvanitakis Z, Schneider JA, Wilson RS, Bienias JL, Kelly JF, Evans DA, et al.: Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology, 2008, 70 (19 Pt 2), 1795-1802.
155. Wu H, Lu D, Jiang H, Xiong Y, Qu C, Li B, et al.: Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury. Journal of Neurotrauma, 2008,25,130-1399.
156. Landreth G: Therapeutic use of agonist of the nuclear receptor PPARgamma in Alzheimer's disease. Current Alzheimer Research, 2007,4,159-164.
157. Jiang Q, Heneka M, Landreth GE: The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications. CNS Drugs, 2008,22,1-14.
158. Sridhar GR, Thota H, Allam AR, Babu CS, Prasad AS, Divakar C: Alzheimer's disease and type 2 diabetes mellitus: the choli- nesterase connection? Lipids Health Disease, 2006,5,28.
159. Rao AA, Sridhar GR, Das UN: Elevated butyrylcholinestera- se and acetylcholinesterase may predict the development of type 2 diabetes mellitus and Alzheimer's disease. Medical Hypotheses, 2007,69,1272-1276.
160. Li L: Is glucagons-like peptide-1 an agent treating diabetes, a new hope for Alzheimer's disease? Neuroscience Bulletin, 2007,23,58-65.
161. Shobab LA, Hsiung GY, Fledman HH: Cholesterol in Alzheimer's disease. Lancet Neurology, 2005,4,841-852.
162. Anghileri E, Marconi S, Pignatelli A, Cifelli P, Galie M, Sbar- bati A, et al.: Neuronal differentiation potential of human adipose-derived mesencymal stem cells. Stem Cells and Development, 2008,17,909-916.
163. Dicou E: Multiple biological activities for two peptides derived from the nerve growth factor precursor. Biochemical and Biophysical Research Communications, 2006,347,833-837.
164. Dicou E: High levels of the proNGF peptides LIP1 and LIP2 in the serum and synovial fluid of rheumatoid arthritis patients: evidence for two new cytokines. Journal of Neuroimmunology, 2008,194,143-146.